The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Several cases of malignant gliomas, testicular and renal cancers showed moderate cytoplasmic immunoreactivity. Remaining malignant cells were weakly stained or negative.
Most of the malignant cells displayed weak to moderate cytoplasmic positivity accompanied with membranous immunoreactivity. A majority of malignant gliomas, lymphomas and melanomas as well as renal cancers were negative.
A majority of malignant cells displayed weak to moderate cytoplasmic and membranous immunoreactivity. Several cases of endometrial, testicular and pancreatic cancers exhibited strong positivity.
Most of the malignant cells displayed weak to moderate cytoplasmic positivity. Most malignant lymphomas, prostate and renal caners as well as several hepatocellular carcinomas were negative.
Most malignant cells displayed moderate to strong cytoplasmic staining, often with a granular pattern. Strongest positivity was observed in endometrial, pancreatic and liver cancers.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
